Pharmaceuticals Protein Production Small Molecule 
Drug Target Review
NOVEMBER 1, 2023
The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.
Dark Matter Blog
JULY 16, 2021
My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 17, 2022
According to SkyQuest Technology, the pharmaceutical industry is worth an estimated $2 trillion dollars and is expected to grow at 5% a year to 2025. It shows that the synthetic biology market was valued at US$9.5 billion in 2020, and it is expected to reach a value of US$38.7 billion by 2027. .
Drug Discovery World
APRIL 30, 2024
The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market. J Biomed Sci 2023;30;84.
Drug Discovery World
JANUARY 12, 2023
Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . Small molecule drugs or biologics need to be delivered via blood vessels and penetrate tissue to get into cells.
Drug Discovery World
NOVEMBER 13, 2023
Michael Traxlmayr, PhD, Group leader, CD Laboratory for Next-Generation CAR T Cells, University of Natural Resources & Life Sciences, on: ‘Novel concepts to regulate CAR T cell activity with small molecule drugs in vivo’. These topics include: High-throughput (HTP) protein production and AI and automation in bioprocess development.
The Pharma Data
OCTOBER 14, 2020
15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. About Eloxx Pharmaceuticals. Eloxx Pharmaceuticals, Inc. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. SOURCE: Eloxx Pharmaceuticals, Inc. WALTHAM, Mass., Conference ID : 9467336. Source link.
Expert insights. Personalized for you.
96 
Let's personalize your content